Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer

Annals of Agricultural and Environmental Medicine

Volumn 20, Issue 2, 2013, Pages 293-297

  Thielemann, Anna ^a   Baszczuk, Aleksandra ^a   Kopczyński, Zygmunt ^a   Kopczyński, Przemysław ^a   Grodecka Gazdecka, Sylwia ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; Tumour metastasis; VEGF

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84878921048     PISSN: 12321966     EISSN: 18982263     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Barańska P, Jerczyńska H, Pawłowska Z. Vascular endothelial growth factor-structure and functions. Post Bioch. 2005; 51: 12-21.
2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nature Rev. 2002; 2: 795-803.
3. Esteva F J, Hortobagyi G N. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004; 6: 109-118.
4. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, Ernst A de Bruijn. Vascular Endothelial Growth Factor and Angiogenesis. Pharmacol Rev. 2004; 56: 549-580.
5. Breier G. Functions of the VEGF/VEGF receptor system in the vascular system. Semin Tromb Hemost. 2000; 26: 553-559.
6. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marmé D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis. 2001; 4: 143-154.
7. Neufeld G, Cohen T, Gengrinovitch S, Poltoraka Z. Vascular Endothelial Growth Factor (VEGF) and its receptor. Faseb J. 1999; 13: 9-22.
8. Bergler-Czop B, Brzezińska-Wcisło L, Syguła E. Evaluation of the nailfold skin capillaroscopic modifications of psoriatic patients and levels of the transforming growth factor α and vascular endothelial growth factor: an initiative paper. Post Dermatol Alergol. 2011; 28: 428-434.
9. McMahon G. VEGF Receptor Signaling in Tumor Angiogenesis. Oncologist. 2000; 5: 3-10.
10. Ferrara N, Gerber H.P, LeCouter J. Te biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676.
11. Horing C, Weich HA. Soluble VEGF receptors. Angiogenesis. 1999; 3: 33-39.
12. Rajkumar T. Growth factors and growth factor receptors in cancer. Curr Sci. 2001; 81: 535-541.
13. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006; 312: 549-560.
14. Folkmann J. Angiogenesis-dependent diseases. Semin Oncol. 2001; 28: 536-542.
15. Bałan B, Słotwiński R. VEGF and tumor angiogenesis. Centr Eur J Immunol. 2008; 33: 232-236.
16. Wu H, Li Y, Zhu G, Zhang L, Zhang X, He X. Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma. Zhonghua Yi Xue Za Zhi 2002; 82: 708-711.
17. Hicklin DJ, Ellis LM. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. J Clin Oncol. 2005; 23: 1011-1027.
18. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer. 2010; 106: 8-18.
19. Otrock Z K, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007; 38: 258-268.
20. Li X, Claesson-Welsh, Shibuya M. VEGF receptor signal transduction. Methods Enzymol. 2008; 443: 261-284.
21. Korzeniewska M, Kołomecki K, Stepień H, Naze M, Stepień T, Kuzdak K. Assessement of pro-and antyangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors. Polish J Endocrinol. 2005; 1: 39-44.
22. Tielemann A, Kopczyński Z, Baszczuk A, Ćwiklińska K, Grodecka-Gazdecka S. Assessment of sVEGFR-1 concentration in patients with breast cancer. Współ Onkol. 2010; 14: 189-195.
23. Kumar H, Heer K, Greenman J, Kerin M, Monson J. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res. 2002; 22: 1877-1880.
24. Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer. 2002; 98: 14-18.
25. Belgore FM, Lip GY, Bareford D. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. Am J Hematol. 2001; 1(66): 59-61.
26. Gershtein ES, Scherbakov AM, Anurova OA, Krasilńikov MA, Kushlinsky NE. Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels. Int J Biol Markers. 2006; 21: 12-19.
27. Benoy I, Salgado R, Colpaert C. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002; 1: 311-316.
28. Fuhrmann-Benzakein H, Ma-Hn, Rubba-Brandt L. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer. 2000; 1: 40-45.
29. Rmali KA, Puntis MCA, Jiang W. Level of the expression of VEGF-A, B, C, D and their receptors (FLT-1, KDR and FLT-4) and its correlation with prognosis in patients with colorectal cancer. Int Cancer Res. 2006; 2: 31-34.
30. Meunier- Carpentier S, Dales J P, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol. 2005; 26: 977-984.
31. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 2008; 82: 8124-1837.